Lv2
193 积分 2021-07-14 加入
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
3天前
已完结
Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation
12天前
已完结
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
18天前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
2个月前
已完结
Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis
2个月前
已完结
Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
3个月前
已完结
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
4个月前
已完结
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib
6个月前
已完结
Novel Treatment Options for Multiple Myeloma
6个月前
已完结
Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
7个月前
已完结
皖公网安备34019202002308
